Dapoxetine
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Dapoxetine: From Premature Ejaculation to Migraine Disorder
One-Sentence Summary
Dapoxetine is a short-acting SSRI originally developed and used on an “as-needed” basis for premature ejaculation. TxGNN predicts it may also be effective for migraine disorder, but this prediction is currently supported by only 2 publications and no clinical trials, and the underlying mechanistic case is contested in the literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Premature ejaculation (per published literature; no UK licence data on file) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L4 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in structured form (flagged as a data gap). Based on the information that is available, dapoxetine is a selective serotonin reuptake inhibitor (SSRI) whose efficacy in premature ejaculation has been established; mechanistically, this is proposed as the basis for possible applicability to migraine.
Dapoxetine differs from typical SSRIs in that it is designed for rapid onset and rapid clearance (Tmax ~1 hour, with the active parent compound falling quickly from the blood despite a ~19-hour metabolite half-life), reflecting its “on-demand” use for premature ejaculation rather than chronic, steady-state serotonergic modulation. Serotonergic signalling is genuinely relevant to migraine pathophysiology — triptans act on 5-HT1B/1D receptors — but the evidence for SSRIs generally in migraine prevention is weak and inconsistent, and some literature suggests SSRIs may trigger or worsen headache in certain patients.
Taken together, the high TxGNN score most plausibly reflects a graph-level association between the “SSRI class” node and the “serotonin–migraine” node, rather than a dapoxetine-specific pharmacological signal. This should be treated as a hypothesis-generating result rather than evidence of clinical efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33998993 | 2022 | Review | Current Neuropharmacology | Reviews off-label uses of SSRIs, including migraine, as a drug class; does not specifically evaluate dapoxetine in migraine |
| 23504864 | 2013 | Cohort (treatment compliance study) | Urologia | Assesses patient compliance with dapoxetine for premature ejaculation; not related to migraine efficacy |
Neither publication directly evaluates dapoxetine for migraine; both were surfaced as class-level or drug-background evidence.
UK Market Information
Dapoxetine currently holds no UK marketing authorisation (market status: Not Marketed, 0 licences on file). No product, dosage form, or licensed indication data is available for the UK market.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: TFDA/manufacturer warnings and contraindications data are flagged as a Blocking data gap (DG001), which prevents a formal S1 safety evaluation for this candidate at this stage.)
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but supporting evidence is minimal — no clinical trials and only two loosely related publications — and the proposed mechanistic link (short-acting, on-demand SSRI dosing vs. chronic migraine prophylaxis) is pharmacokinetically questionable. The two other top-ranked predictions for this drug (dysthymic disorder, migraine with brainstem aura) have no supporting evidence at all (L5), reinforcing that these may be class-level graph associations rather than drug-specific signals.
To proceed, the following is needed:
- Resolution of the blocking safety data gap (DG001): TFDA/SmPC warnings and contraindications
- Confirmed mechanism of action data (DG002)
- Dedicated preclinical or clinical evidence for dapoxetine specifically in migraine (not extrapolated from the SSRI class)
- UK regulatory pathway assessment, given the drug currently holds no UK marketing authorisation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.